68754-16-5

Basic information

• Product Name: 1-(2-hydroxy-4,6-dimethoxyphenyl)-3-methylbutan-1-one
• Synonyms: 1-(2-hydroxy-4,6-dimethoxyphenyl)-3-methylbutan-1-one
• CAS NO: 68754-16-5
• Molecular Weight: 238.284
• Mol File: 68754-16-5.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 1-(2-hydroxy-4,6-dimethoxyphenyl)-3-methylbutan-1-one(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2-hydroxy-4,6-dimethoxyphenyl)-3-methylbutan-1-one(68754-16-5)
• EPA Substance Registry System: 1-(2-hydroxy-4,6-dimethoxyphenyl)-3-methylbutan-1-one(68754-16-5)

Safety Data

• Hazardous Substances Data: 68754-16-5(Hazardous Substances Data)

Upstream product

• 500-99-2 3,5-dimethoxyphenol 
• 108-12-3 isopentanoyl chloride 
• 590-86-3 isovaleraldehyde 
• 108-73-6 3,5-dihydroxyphenol 
• 503-74-2 3-methylbutyric acid 
• 186581-53-3 diazomethane 
• 26103-97-9 phloroisovalerophenone 
• 77-78-1 dimethyl sulfate 

Downstream Products

• 68754-19-8 2,4-Dimethoxy-benzoic acid 3,5-dimethoxy-2-(3-methyl-butyl)-6-(5-methyl-hexanoyl)-phenyl ester 
• 68754-20-1 1-(2,4-Dimethoxy-phenyl)-3-[2-hydroxy-4,6-dimethoxy-3-(3-methyl-butyl)-phenyl]-2-(3-methyl-butyl)-propane-1,3-dione 
• 68754-18-7 1-[2-Hydroxy-4,6-dimethoxy-3-(3-methyl-butyl)-phenyl]-5-methyl-hexan-1-one 
• 179630-66-1 1-(2-Hydroxy-4,6-dimethoxy-3-propylsulfanylmethyl-phenyl)-3-methyl-butan-1-one 
• 167385-76-4 3,5-Dimethoxy-2-(3-methyl-1-phenylsulfanyl-butyl)-phenol 

Relevant articles and documents

A Novel Parkinson's Disease Drug Candidate with Potent Anti-neuroinflammatory Effects through the Src Signaling Pathway

Numerous drug treatments are available for Parkinson's disease (PD), an age-related neurodegenerative disease, but most cause serious side effects. Therefore, novel therapeutic strategies that halt disease progression and allow for long-term administration are urgently needed. Neuroinflammation critically contributes to the pathogenesis of PD. Here, we report the discovery and optimization of phloroglucinol derivatives, a novel class of anti-neuroinflammatory compounds. Structural modifications of the hit compound 3-methyl-1-(2,4,6-trihydroxyphenyl)butan-1-one produced 43 derivatives, including a preclinical candidate (compound 21), that exhibited potent in vitro anti-neuroinflammatory effects, good blood-brain barrier penetration, and desirable safety margins in mice at a median lethal dose (LD50) >5000 mg/kg. Its in vivo efficacy was demonstrated in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)- and MPTP/probenecid (prob)-induced subacute and chronic PD models, respectively, and α-synuclein transgenic mice. Mechanistic studies revealed neuroinflammation inhibition by targeting Src/phosphatase and tensin homologue deleted on chromosome 10 (PTEN)/Akt signaling might be promising. We highlighted the potential usefulness of phloroglucinol derivatives in PD treatment.

The first total synthesis of sideroxylonal B

Sideroxylonal B (2c) has been synthesized through biomimetic cycloaddition of the o-quinone methide and the isopentenyl intermediates (5 and 6t), both of which were simultaneously derived from isopentenyl phloroglucinol precursor 4.